Nanobiotix S.a. income statement

In fiscal 2025, Nanobiotix S.a. reported revenue of $36.9m, down 573.6% on the year before, operating income of −$12.2m (a -33.2% margin) and net income of −$27.1m, or −$0.57 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Nanobiotix S.a.: income statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	4	3	3	3	5	39	−8	37
Research and development	25	34	28	36	34	42	44	26
Operating income	−36	−52	−42	−62	−49	−29	−74	−12
Interest expense	1	0	0	0	0	0	0	0
Income before tax	−36	−57	−38	−56	−60	−43	−74	−27
Income tax	0	0	0	0	0	0	0	0
Net income	−36	−57	−38	−56	−60	−43	−74	−27
Diluted EPS	−$1.83	−$2.63	−$1.57	−$1.60	−$1.73	−$1.17	−$1.56	−$0.57
Diluted shares (average)	19,633m	22m	24m	35m	35m	37m	47m	48m
EBITDA	−35	−50	−40	−60	−48	−27	−72	−10

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: FHTX vs NBTX NBTX vs ZYME CUE vs NBTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Nanobiotix S.a.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nanobiotix S.a.